Common Drug Review *

Submission Status

Product: Januvia

Generic Name: sitagliptin phosphate

Manufacturer: Merck Frosst Canada Ltd.

Submission Type: New

Date Submission Received: 2007-Dec-20 **Date NOC Issued:** 2007-Dec-14

Targeted CEDAC Meeting: 2008-Jun-18 **Priority Review Granted:** Not Requested

	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	Submission Assessment	5	2008-Jan-07	2008-Jan-07	Category 1 requirements deemed incomplete January 7, 2008.
	Submission deemed complete			2008-Jan-15	Submission deemed complete January 15, 2008. Submission placed in queue in accordance with CDR procedures. Review to be initiated pending availability of resources. Reference requested January 24, 2008. Reference received January 25, 2008. Review initiated February 12, 2008.
2	CDR Reviewers' Reports Completed • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer	45	2008-Apr-17	2008-Apr-04	Additional information requested February 4, 2007. Additional information received February 5, 2007. Additional information requested March 3, 2008. Additional information received March 14, 2008. Revised information received March 17, 2008. Additional information requested March 18, 2008. Additional information received March 31, 2008.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2008-Apr-28	2008-Apr-15	Due date for manufacturer's comments April 15, 2008.
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2008-Apr-24	2008-Apr-24	
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2008-May-06	2008-May-06	
6	CEDAC Meeting		2008-May-21	2008-May-21	CEDAC Meeting changed from June 18, 2008 to May 21, 2008.
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2008-May-28	2008-May-28	
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Reques for Clarification of the Recommendation and Reasons for Recommendation	10	2008-Jun-11	2008-Jun-11	
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5	2008-Jun-18	2008-Jun-18	Notice of Final Recommendation issued.
	OR				
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.

Reflects updates as of Thursday noon.